EAM Investors’s Endocyte, Inc. Common Stock ECYT Stock Holding History

EAM Investors’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-63,849	Closed	-$1.13M	–	370
2018 Q3	$1.13M	Hold	63,849	–	–	0.17%	205
2018 Q2	$881K	Buy	+63,849	New	+$758K	0.14%	218
2018 Q1	–	Sell	-98,034	Closed	-$420K	–	408
2017 Q4	$420K	Buy	+98,034	New	+$467K	0.08%	296
2013 Q4	–	Sell	-64,969	Closed	-$866K	–	385
2013 Q3	$866K	Sell	64,969 -112	-0.2%	-$1.77K	0.17%	300
2013 Q2	$855K	Buy	+65,081	New	+$878K	0.19%	290

Other funds holding ECYT

OTC

Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return

Claro Advisors Boston, Massachusetts $830M AUM 21.8% 1-Year Est. Return

EAM Investors's ECYT Position: Q4 2018 in Review

EAM Investors sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2018, closing a stake of 63,849 shares — an estimated $1.13M sold.

EAM Investors first reported a position in ECYT in Q2 2013 and held it in 5 quarters. The position peaked at $1.13M in Q3 2018. 2 funds tracked by Wall St. Rank hold ECYT as of Q4 2018.

EAM Investors reported no remaining Endocyte, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
EAM Investors sold 63,849 Endocyte, Inc. Common Stock shares in Q4 2018, an estimated $1.13M.
EAM Investors first reported a position in Endocyte, Inc. Common Stock in Q2 2013 and held it in 5 quarters.
EAM Investors's Endocyte, Inc. Common Stock position peaked at $1.13M in Q3 2018.
2 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2018.

Based on EAM Investors's 13F filing for Q4 2018, filed 13 Feb 2019.